OBJECTIVE: Given that control of blood glucose improves long-term outcomes for patients diagnosed with type-2 diabetes, the objective of this study is to examine levels of glycemic control and antidiabetic medication use in Germany. METHODS: Data for this study were obtained from the German Disease Analyzer - Mediplus database. All patients who were identified with type-2 diabetes between January 1, 2004 and December 31, 2004, were at least 20 years of age, and received at least one HbA1c test between April 1, 2004 and December 31, 2004 were included in the analysis (N=5,135). Medication use was examined for the 90 days prior to the individual's most recent HbA1c test. RESULTS: Among those patients who were treated with antidiabetic medication (61.93%), individuals were most commonly prescribed metformin monotherapy (33.55%), sulfonylurea monotherapy (18.18%), oral combination therapy (17.68%), insulin monotherapy (16.92%), or insulin plus oral therapy (7.13%). Over half of all patients diagnosed with type-2 diabetes (52.74%) did not obtain a recommended range of glycemic control of 6.5% or below. Comparing patients who were within the recommended range of glycemic control to those above the targeted range revealed no significant differences in mean age, sex, or comorbidities reported in 2004. In contrast, there were significant differences in the percentage of patients who obtained the recommended range of glycemic control based on antidiabetic medication prescribed (p<0.0001). Patients treated with insulin combination therapy or insulin monotherapy were least likely to be within the targeted range of HbA1c (22.91% and 26.58%, respectively), while only 31.85% of those treated with oral combination therapy were within the targeted range. CONCLUSIONS: Over half of patients diagnosed with type-2 diabetes do not achieve the targeted range of glycemic control. For a majority of patients, alternative therapy regimens seem necessary to achieve good glycemic control.